Retrieve available abstracts of 208 articles: HTML format
Single Articles
May 2025
SCARADAVOU A Cord blood transplants: Advancing leukaemia treatments and addressing health
disparities.
Br J Haematol. 2025;206:1312-1314. PubMedAbstract available
ZHENG Z, Wang W, Feng M, Chen X, et al The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8(+) T cell
exhaustion to participate in the transformation from myelodysplastic syndrome to
acute myeloid leukaemia.
Br J Haematol. 2025;206:1335-1349. PubMedAbstract available
VICENTE-GARCES C, Fernandez G, Esperanza-Cebollada E, Richarte-Franques M, et al RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric
B-other acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:1355-1365. PubMedAbstract available
LIU J, Zhao XS, Chang YJ, Qin YZ, et al Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse
and survival risk after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:1418-1429. PubMedAbstract available
SUTTORP M, Sembill S, Lensker P, Hildebrand V, et al Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia:
Data from a real-world setting.
Br J Haematol. 2025;206:1397-1405. PubMedAbstract available
STASIK S, Eckardt JN, Rollig C, Baldus CD, et al The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular
profile in adult patients with AML.
Br J Haematol. 2025;206:1373-1379. PubMedAbstract available
April 2025
ZHAO C, Xiao MY, Zhang F, Bai L, et al Outcomes and prognostic factors associated with relapse after haploidentical stem
cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:1165-1172. PubMedAbstract available
CONNERTY P, Xie J, El-Najjar F, Trahair TN, et al Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in
xenograft models of paediatric acute myeloid leukaemia.
Br J Haematol. 2025;206:1092-1096. PubMedAbstract available
PRATZ KW Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
Br J Haematol. 2025;206:1250-1252. PubMedAbstract available
FRERICH C, Li P, Raess PW, Dunlap J, et al Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult
acute myeloid leukaemia.
Br J Haematol. 2025;206:1097-1102. PubMedAbstract available
DE BOTTON S, Recher C, Cortes J, Curti A, et al Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute
myeloid leukaemia arising from a prior myeloproliferative neoplasm.
Br J Haematol. 2025;206:1121-1128. PubMedAbstract available
March 2025
PERUTELLI F, Boccellato E, Montalbano MC, Catania G, et al Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after
allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:924-929. PubMedAbstract available
SERAFIN A, Ruocco V, Cellini A, Angotzi F, et al Management strategies for patients with chronic lymphocytic leukaemia harbouring
complex karyotype.
Br J Haematol. 2025;206:832-841. PubMedAbstract available
VALTIS YK, Luskin MR Better late than never: Delayed asparaginase during induction for acute
lymphoblastic leukaemia in adults.
Br J Haematol. 2025;206:1016-1017. PubMedAbstract available
LAING A, Elmarghany A, Alghaith AA, Gouma A, et al Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia
cell survival and enhance chemoresistance via contact-independent mechanism.
Br J Haematol. 2025;206:858-863. PubMedAbstract available
TINAJERO J, Xu S, Ngo D, Li S, et al Delaying pegaspargase during induction in adults with acute lymphoblastic
leukaemia is associated with lower risk of high-grade hepatotoxicity without
adversely impacting outcomes.
Br J Haematol. 2025;206:868-875. PubMedAbstract available
February 2025
ZHAO J, Liu TF, Wu KF, Yang LC, et al Clinical and molecular characteristics of paediatric mature B-cell acute
lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A
joint study between the CCCG leukaemia and lymphoma groups.
Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011. PubMedAbstract available
CHEN Z, Ren A, Li Y, Shu J, et al mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for
the eradication of leukaemic cells.
Br J Haematol. 2025;206:628-643. PubMedAbstract available
LIN CC, Hsu CL, Yao CY, Wang YH, et al HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:505-516. PubMedAbstract available
GANZEL C, Frisch A, Wolach O, Moshe Y, et al CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with
newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot
study.
Br J Haematol. 2025;206:551-555. PubMedAbstract available
GURNARI C, Visconte V Dissecting the genomic traits and clinical course of secondary myelodysplastic
syndrome following aplastic anaemia: A milestone.
Br J Haematol. 2025;206:790-791. PubMedAbstract available
ESTELLER M Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new
kids on the block.
Br J Haematol. 2025;206:785-787. PubMedAbstract available
CHEN X, Gong RZ, Mo LY, Cheng YT, et al Hydroxy-wybutosine tRNA modifications as indicators of disease progression and
therapeutic targets in leukaemia.
Br J Haematol. 2025;206:517-530. PubMedAbstract available
January 2025
SWEET K, Cluzeau T Clinical perspectives on post-induction maintenance therapy in patients with
acute myeloid leukaemia in remission who are ineligible for allogeneic
haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:61-68. PubMedAbstract available
COSTA A, Scalzulli E, Breccia M Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features,
genomic insight and therapeutic strategies.
Br J Haematol. 2025;206:44-60. PubMedAbstract available
HA TQ, Andresen V, Erikstein BS, Popa M, et al Preclinical activity of resazurin in acute myeloid leukaemia.
Br J Haematol. 2025;206:109-119. PubMedAbstract available
JIANG L, Cheng J, Sun J, Zhang Y, et al Dynamics of measurable residual disease for risk stratification and guiding
allogeneic transplant in acute myeloid leukaemia patients with
myelodysplasia-related mutations in first remission.
Br J Haematol. 2025;206:250-262. PubMedAbstract available
VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al Real-world experience of paediatric acute promyelocytic leukaemia in the United
Kingdom and Ireland.
Br J Haematol. 2025;206:204-208. PubMedAbstract available
DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al Measurable residual disease-driven treatment in first-line chronic lymphocytic
leukaemia.
Br J Haematol. 2025;206:33-43. PubMedAbstract available
TRKA J, Fronkova E Minimal residual disease detection for acute lymphoblastic leukaemia in
peripheral blood-Are we there yet?
Br J Haematol. 2025;206:397-398. PubMedAbstract available
HUANG Q, Jiang X, Wang B, Wu Z, et al Gallic acid enhances GVL effects of T cells without exacerbating GVHD after
haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:120-132. PubMedAbstract available
THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al Secondary haematological dysplasia after CAR-T-cell therapy for acute
lymphoblastic leukaemia in children.
Br J Haematol. 2025;206:186-194. PubMedAbstract available
COUSSON S, Calvo C, Goldwirt L, Simonin M, et al Monocentric experience of venetoclax-based regimen in paediatric refractory and
relapsed AML/MDS.
Br J Haematol. 2025;206:209-214. PubMedAbstract available
December 2024
FROST EL, Chonat S, Williams KM, Aumann W, et al Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A
case report and review of vascular complications in germline GATA2
haploinsufficiency.
Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935. PubMed
HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al Clinical outcomes in patients in any phase of CML treated with ponatinib in
France-Data from the TOPASE observational study.
Br J Haematol. 2024;205:2295-2304. PubMedAbstract available
MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide
versus HLA-matched unrelated donors in peripheral blood stem cell transplantation
for acute myeloid leukaemia.
Br J Haematol. 2024;205:2376-2386. PubMedAbstract available
KONDO T A new face in the treatment of Philadelphia chromosome-positive acute
lymphoblastic leukaemia.
Br J Haematol. 2024;205:2131-2133. PubMedAbstract available
PULA AE, Robak T The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2)
chromosomal translocation.
Br J Haematol. 2024;205:2125-2127. PubMedAbstract available
BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
Br J Haematol. 2024;205:2153-2162. PubMedAbstract available
JAYNE S, Lopez C, Put N, Nagel I, et al The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic
lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
Br J Haematol. 2024;205:2321-2326. PubMedAbstract available
TERUEL-MONTOYA R, Rivera J, Lozano ML The importance of genetic variant cleaners: From patient to wet lab and back to
clinical practice.
Br J Haematol. 2024;205:2122-2124. PubMedAbstract available
KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al Two novel families with RUNX1 variants indicate glycine 168 as a new mutational
hotspot: Implications for FPD/AML diagnosis.
Br J Haematol. 2024;205:2315-2320. PubMedAbstract available
LIU W, Wang C, Ouyang W, Hao J, et al Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I
mutation or relapsed/refractory disease.
Br J Haematol. 2024;205:2228-2233. PubMedAbstract available
ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and
outcomes in the era of immunotherapy.
Br J Haematol. 2024;205:2234-2247. PubMedAbstract available
November 2024
LV M, Yan CH, Ma R, He Y, et al Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for
patients with relapsed/refractory AML with active disease at the time of
allogeneic haematopoietic cell transplantation: A multicenter prospective phase
II study.
Br J Haematol. 2024;205:1910-1920. PubMedAbstract available
BOULIGNY IM, DiNardo CD Oral decitabine-cedazuridine in acute myeloid leukaemia.
Br J Haematol. 2024;205:1674-1676. PubMedAbstract available
GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid
leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Br J Haematol. 2024;205:1734-1745. PubMedAbstract available
PHILIP C, Selvarajan S, Nayak L, Jain H, et al Impact of the COVID-19 pandemic on treatment of patients with acute myeloid
leukaemia in India.
Br J Haematol. 2024;205:2058-2062. PubMedAbstract available
YANADA M Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in
acute promyelocytic leukaemia.
Br J Haematol. 2024;205:1672-1673. PubMedAbstract available
MAILLET F, Galimard JE, Borie R, Lainey E, et al Haematological features of telomere biology disorders diagnosed in adulthood: A
French nationwide study of 127 patients.
Br J Haematol. 2024;205:1835-1847. PubMedAbstract available
ARIFFIN H Incorrigible inflammation.
Br J Haematol. 2024;205:1679-1680. PubMedAbstract available
CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic
trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and
treatment-related complications.
Br J Haematol. 2024;205:1727-1733. PubMedAbstract available
SPECTOR LG, de Smith AJ Backtracking childhood leukaemia to birth: A battle of addition.
Br J Haematol. 2024;205:1670-1671. PubMedAbstract available
YANG YT, Yao CY, Kao CJ, Chiu PJ, et al Clinical relevance of NFYA splice variants in patients with acute myeloid
leukaemia undergoing intensive chemotherapy.
Br J Haematol. 2024;205:1751-1764. PubMedAbstract available
XU N, Dao FT, Shi ZY, Sun K, et al WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute
myeloid leukaemia.
Br J Haematol. 2024;205:1848-1859. PubMedAbstract available
ZHU Q, Nambiar R, Schultz E, Gao X, et al Genome-wide study identifies novel genes associated with bone toxicities in
children with acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:1889-1898. PubMedAbstract available
BARDINI M, Fazio G, Abascal LC, Meyer C, et al Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute
lymphoblastic leukaemia.
Br J Haematol. 2024;205:1883-1888. PubMedAbstract available
WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients
treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
Br J Haematol. 2024;205:1746-1750. PubMedAbstract available
October 2024
YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al Comparative outcomes of various transplantation platforms, highlighting
haploidentical transplants with post-transplantation cyclophosphamide for adult
T-cell leukaemia/lymphoma.
Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835. PubMedAbstract available
NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM
rearrangement using patient-specific iPSCs.
Br J Haematol. 2024;205:1430-1443. PubMedAbstract available
GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton
tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
Br J Haematol. 2024;205:1395-1403. PubMedAbstract available
GAO MY, Georgiou A, Lin VS, Jahja M, et al Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic
lymphocytic Leukaemia: In vitro insights and clinical implications.
Br J Haematol. 2024;205:1389-1394. PubMedAbstract available
MEHTA P, Campbell V, Maddox J, Floisand Y, et al CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for
first-line treatment of newly diagnosed therapy-related AML and AML with
myelodysplasia-related changes in the UK.
Br J Haematol. 2024;205:1326-1336. PubMedAbstract available
ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al Severe steroid-related neuropsychiatric symptoms during paediatric acute
lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working
Group Study.
Br J Haematol. 2024;205:1450-1459. PubMedAbstract available
September 2024
NARESH KN Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli:
Diagnosis, underpinnings for disease classification and future directions.
Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754. PubMedAbstract available
HEI Z, Yang S, Ouyang G, Hanna J, et al Targeting the redox vulnerability of acute myeloid leukaemia cells with a
combination of auranofin and vitamin C.
Br J Haematol. 2024;205:1017-1030. PubMedAbstract available
LEBLANC FR, Breese EH, Burns KC, Chang EK, et al Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed
unfit and relapsed/refractory paediatric, adolescent and young adult acute
myeloid leukaemia patients.
Br J Haematol. 2024;205:1055-1066. PubMedAbstract available
HUANG C, Jia Y, Yang J, Cai Y, et al Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after
allogeneic peripheral blood stem cell transplantation: A prospective phase II
study.
Br J Haematol. 2024;205:1067-1076. PubMedAbstract available
GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al Dasatinib induces endothelial dysfunction leading to impaired recovery from
ischaemia.
Br J Haematol. 2024;205:1011-1016. PubMedAbstract available
KUGLER E, Cohen I, Amitai I, Ram R, et al Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated
acute myeloid leukaemia.
Br J Haematol. 2024;205:932-941. PubMedAbstract available
KUHN MWM, Ganser A The Menin story in acute myeloid leukaemia-The road to success.
Br J Haematol. 2024;205:812-814. PubMedAbstract available
ZHAO S, Wang J, Lou Y, Huang X, et al Clinical characteristics of acute myeloid leukaemia patients with a large number
of azurophilic granules: A single-centre retrospective study.
Br J Haematol. 2024;205:924-931. PubMedAbstract available
ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al Expectations and outcomes of varying treatment strategies for CML presenting
during pregnancy.
Br J Haematol. 2024;205:947-955. PubMedAbstract available
MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular
lymphocytic leukaemia.
Br J Haematol. 2024;205:915-923. PubMedAbstract available
August 2024
GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute
myeloid leukaemia with NPM1 mutation.
Br J Haematol. 2024;205:401-402. PubMed
YANG F, Ren Q, Zu Y, Gui R, et al Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after
autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
Br J Haematol. 2024;205:645-652. PubMedAbstract available
TRINQUAND A, Betts DR, Rooney S, Storey L, et al MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell
acute lymphoblastic leukaemia: A national cohort analysis.
Br J Haematol. 2024;205:729-732. PubMed
CHEN C, Li J, Chen Y, Gao Q, et al The correlation of asparaginase enzyme activity levels after PEG-asparaginase
administration with clinical characteristics and adverse effects in Chinese
paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:624-633. PubMedAbstract available
ZHU W, Ding Y, Huang W, Guo N, et al Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503
against MLL::AF9-driven acute myeloid leukaemia.
Br J Haematol. 2024;205:568-579. PubMedAbstract available
GRADY E, Biswas S, Dias T, McCarthy P, et al A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in
paediatric B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:738-741. PubMed
OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell
therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:711-715. PubMed
WANG S, Liu Y, Zhao X, Wang X, et al RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a
therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Br J Haematol. 2024;205:552-567. PubMedAbstract available
TANG FF, Duan WB, Liu XH, Lu SY, et al A complete oral regimen for induction therapy of patients with high-risk APL: An
oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
Br J Haematol. 2024;205:510-516. PubMedAbstract available
NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic
leukaemia patients without 17p deletion treated with chemoimmunotherapy in two
prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Br J Haematol. 2024;205:495-502. PubMedAbstract available
XU X, Huang Z, Ding C, Deng S, et al STAT5 phosphorylation plus minimal residual disease defines a novel risk
classification in adult B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:517-528. PubMedAbstract available
BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3
activation.
Br J Haematol. 2024;205:607-612. PubMedAbstract available
July 2024
ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy
resistance in acute myeloid leukaemia.
Br J Haematol. 2024;205:207-219. PubMedAbstract available
RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al Early blast clearance during sequential conditioning prior to allogeneic stem
cell transplantation in patients with acute myeloid leukaemia.
Br J Haematol. 2024;205:280-290. PubMedAbstract available
JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al Evaluation of European LeukemiaNet 2022 risk classification in patients
undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid
leukaemia: Identification of a very poor prognosis genetic group.
Br J Haematol. 2024;205:256-267. PubMedAbstract available
PICHLER H, Sedlacek P, Meisel R, Beier R, et al Haematopoietic stem cell transplantation after reduced intensity conditioning in
children and adolescents with chronic myeloid leukaemia: A prospective
multicentre trial of the I-BFM Study Group.
Br J Haematol. 2024;205:268-279. PubMedAbstract available
TAURINO G, Dander E, Chiu M, Pozzi G, et al Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for
BCP-ALL cell survival and a potential therapeutic target.
Br J Haematol. 2024;205:175-188. PubMedAbstract available
WANG HY, Louis HMS, Costello CL, Murray SS, et al A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A
without rearrangement: A case report and review of the English literature.
Br J Haematol. 2024;205:364-367. PubMed
DOURTHE ME, Yakouben K, David A, Thouvenin S, et al Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells
(tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:373-377. PubMed
JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al Combination therapy with novel agents for acute myeloid leukaemia: Insights into
treatment of a heterogenous disease.
Br J Haematol. 2024;205:30-47. PubMedAbstract available
SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al Exploring the prognostic role of complex karyotype in chronic lymphocytic
leukaemia patients treated with venetoclax-based regimens.
Br J Haematol. 2024;205:189-193. PubMedAbstract available
ZHANG X, Zhong Y, Liu L, Suo S, et al MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to
venetoclax: A case report.
Br J Haematol. 2024;205:352-355. PubMed
IYENGAR L, Fong CY, Prakash S, Chong AH, et al Cutaneous involvement in chronic lymphocytic leukaemia.
Br J Haematol. 2024;205:11. PubMed
POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al Therapy-related acute lymphoblastic leukaemia in women with antecedent breast
cancer.
Br J Haematol. 2024;205:158-165. PubMedAbstract available
June 2024
XU J, Peng J, Sun S, Wang D, et al Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of
T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:2301-2318. PubMedAbstract available
DELGADO J InsT-ALLing CD7 chimeric antigen receptors before transplantation.
Br J Haematol. 2024;204:2155-2156. PubMedAbstract available
ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al Combining 5-azacitidine with the E-selectin antagonist uproleselan is an
effective strategy to augment responses in myelodysplasia and acute myeloid
leukaemia.
Br J Haematol. 2024;204:2264-2274. PubMedAbstract available
ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al A 4-gene prognostic index for enhancing acute myeloid leukaemia survival
prediction.
Br J Haematol. 2024;204:2287-2300. PubMedAbstract available
LIU H, Wu K, Hu W, Chen X, et al Immunophenotypic clustering in paediatric acute myeloid leukaemia.
Br J Haematol. 2024;204:2275-2286. PubMedAbstract available
MAO S, Lin Y, Qin X, Miao Y, et al Droplet digital PCR: An effective method for monitoring and prognostic evaluation
of minimal residual disease in JMML.
Br J Haematol. 2024;204:2332-2341. PubMedAbstract available
JEN WY, Sasaki K, Loghavi S, Wang SA, et al Characteristics and outcomes of acute myeloid leukaemia patients with baseline
CD7 expression.
Br J Haematol. 2024;204:2259-2263. PubMedAbstract available
KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al Strategies to reduce relapse risk in patients undergoing allogeneic stem cell
transplantation for acute myeloid leukaemia.
Br J Haematol. 2024;204:2173-2183. PubMedAbstract available
ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3'
induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I
study.
Br J Haematol. 2024;204:2254-2258. PubMedAbstract available
ONIDA F, Gras L, Ge J, Koster L, et al Mismatched related donor allogeneic haematopoietic cell transplantation compared
to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis
from the Chronic Malignancies Working Party of the EBMT.
Br J Haematol. 2024;204:2365-2377. PubMedAbstract available
HARROP S, Nguyen PC, Robinson S, Nguyen T, et al Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem
duplications.
Br J Haematol. 2024;204:2492-2495. PubMed
BARNBROCK A, Moricke A, Barbaric D, Jones N, et al Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A
report from the multi-international clinical trial AIEOP-BFM ALL 2009.
Br J Haematol. 2024;204:2319-2323. PubMedAbstract available
DONG Q, Wang Y, Xiu Y, Wu X, et al Unveiling myeloid transformation: T-LGLL with eosinophilia masking
myeloid-associated STAT5B mutation culminating in AML.
Br J Haematol. 2024;204:2487-2491. PubMed
BAUCH T, Hempel G Proof of concept of physiologically based pharmacokinetic modelling in paediatric
acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:2324-2331. PubMedAbstract available
May 2024
RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al Older age, CNS leukaemic involvement and induction tumour lysis increases the
risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic
leukaemia/lymphoma: Experience from a tertiary care centre in South India.
Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559. PubMedAbstract available
BALDUZZI A The CAR T-cell race: The rules of the game.
Br J Haematol. 2024;204:1579-1581. PubMedAbstract available
ZHANG X, Tao C, Long F Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with
hydroxycarbamide.
Br J Haematol. 2024;204:1569-1570. PubMed
MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al Practice guideline: Preparation for CAR T-cell therapy in children and young
adults with B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1687-1696. PubMedAbstract available
KRIEGER E, Qayyum R, Toor A Increased donor inhibitory KIR are associated with reduced GVHD and improved
survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
Br J Haematol. 2024;204:1935-1943. PubMedAbstract available
LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow
cytometric 12-colour tube improves diagnosis and minimal residual disease
follow-up.
Br J Haematol. 2024;204:1872-1881. PubMedAbstract available
JO T, Ueda T, Akahoshi Y, Kondo T, et al First complete remission favours haploidentical haematopoietic stem cell
transplantation with post-transplant cyclophosphamide over cord blood
transplantation in acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1913-1919. PubMedAbstract available
BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al HLA peptide-binding pocket diversity modulates immunological complications after
cord blood transplant in acute leukaemia.
Br J Haematol. 2024;204:1920-1934. PubMedAbstract available
BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al The role of chimeric antigen receptor T cells targeting more than one antigen in
the treatment of B-cell malignancies.
Br J Haematol. 2024;204:1649-1659. PubMedAbstract available
LOH Z, Ashby M, Van Veldhuizen E, Li W, et al Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
Br J Haematol. 2024;204:1732-1739. PubMedAbstract available
April 2024
HUO W, Gao L, Song K, Huang J, et al Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic
lymphoma: A real-world multicentre analysis in China.
Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481. PubMedAbstract available
CAO XY, Zhang JP, Lu Y, Zhao YL, et al A safety and efficacy study of allogeneic haematopoietic stem cell
transplantation for refractory and relapsed T-cell acute lymphoblastic
leukaemia/lymphoblastic lymphoma patients who achieved complete remission after
autologous CD7 chimeric antigen r
Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445. PubMedAbstract available
LIU HC, Huang YJ, Jaing TH, Wu KH, et al Refining risk stratification in paediatric B-acute lymphoblastic leukaemia:
Combining IKZF1(plus) and Day 15 MRD positivity.
Br J Haematol. 2024;204:1344-1353. PubMedAbstract available
BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al Relevance of CD20 antigen expression among paediatric patients with B-lineage
acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1367-1374. PubMedAbstract available
CHEN X, Li J, Yu L, Hu W, et al High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric
acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Br J Haematol. 2024;204:1354-1366. PubMedAbstract available
MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al Validation of the Artificial Intelligence Prognostic Scoring System for
Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach
for improved risk stratification.
Br J Haematol. 2024;204:1529-1535. PubMedAbstract available
STENTOFT J The Mozart effect in chronic myeloid leukaemia.
Br J Haematol. 2024;204:1139-1140. PubMedAbstract available
PATEL SA The heart of VIALE-A: Cardiac complications of hypomethylating agents and
venetoclax in acute myeloid leukaemia.
Br J Haematol. 2024;204:1137-1138. PubMedAbstract available
ZHANG T, Zhang Y, Zhou M, Zhang Z, et al Risk factors and survival analysis of human leukocyte antigen loss in relapsed
acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic
haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:1402-1413. PubMedAbstract available
ALCAZER V, Morisset S, Rea D, Legros L, et al Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in
chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024;204:1536-1539. PubMed
JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with
venetoclax + hypomethylating agents.
Br J Haematol. 2024;204:1232-1237. PubMedAbstract available
NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al Venetoclax resistance in acute myeloid leukaemia-Clinical and biological
insights.
Br J Haematol. 2024;204:1146-1158. PubMedAbstract available
ZUCENKA A, Griskevicius L Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin
D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:1227-1231. PubMedAbstract available
SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al Quantitative computed tomography analysis of body composition changes in
paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1335-1343. PubMedAbstract available
FIEDLER W Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed
acute myeloid leukaemia requiring admission to the intensive care unit: Possible
reduction in side effects with preserved efficacy.
Br J Haematol. 2024;204:1135-1136. PubMedAbstract available
LIANG P, Xie Y, Liu Z, Wang D, et al Venetoclax and hypomethylating agents in critically ill patients with newly
diagnosed acute myeloid leukaemia.
Br J Haematol. 2024;204:1219-1226. PubMedAbstract available
ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al Treatment and follow-up of children with chronic myeloid leukaemia in chronic
phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of
experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Br J Haematol. 2024;204:1249-1261. PubMedAbstract available
MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH
inhibitors.
Br J Haematol. 2024;204:1238-1242. PubMedAbstract available
LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al Early clearance of hairy cell leukaemia in the bone marrow after first-line
treatment with cladribine predicts a favourable outcome.
Br J Haematol. 2024;204:1288-1292. PubMedAbstract available
March 2024
LARIBI K, Poulain S, Willems L, Merabet F, et al Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and
rituximab: A study on behalf of the French Innovative Leukemia Organization
(FILO).
Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409. PubMedAbstract available
NG HL, Robinson ME, May PC, Innes AJ, et al Promoter-centred chromatin interactions associated with EVI1 expression in
EVI1+3q- myeloid leukaemia cells.
Br J Haematol. 2024;204:945-958. PubMedAbstract available
SUN H, Zhu Y, Li J, Zhao L, et al CSF3R P733T is a deleterious germline variant in acute leukaemia showing
gain-of-function-like T618I mutation.
Br J Haematol. 2024;204:e31-e33. PubMed
SHIMONY S, Chen EC Tri-ing to decipher trisomy AML.
Br J Haematol. 2024;204:751-752. PubMedAbstract available
TAN JY, Yeo YH, Tan MC, Chavez JC, et al Mortality trends of chronic lymphocytic leukaemia in the United States with the
emergence of targeted therapy.
Br J Haematol. 2024;204:1114-1117. PubMed
ZHAO HG Should oligomonocytic CMML be classified as an independent disease entity?
Br J Haematol. 2024;204:749-750. PubMedAbstract available
LAM SSY, Tsui SP, Fung CY, Saw NY, et al Distinct karyotypic and mutational landscape in trisomy AML.
Br J Haematol. 2024;204:939-944. PubMedAbstract available
COPLAND M, Ariti C, Thomas IF, Upton L, et al A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus
single-agent low-dose cytosine arabinoside in older patients with acute myeloid
leukaemia: Results from the LI-1 trial.
Br J Haematol. 2024;204:871-876. PubMedAbstract available
CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al Characteristics and long-term outcome in a large series of chronic myelomonocytic
leukaemia patients including 104 formerly referred to as oligomonocytic.
Br J Haematol. 2024;204:892-897. PubMedAbstract available
LU Q, Qu W, Wen Y, Ke P, et al Single-cell RNA-seq reveals the links between the metabolic heterogeneity and
cell identity in NBM and AML.
Br J Haematol. 2024;204:1100-1104. PubMed
RAVANDI F, Dohner H, Wei AH, Montesinos P, et al Survival outcomes in patients with acute myeloid leukaemia who received
subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol. 2024;204:877-886. PubMedAbstract available
MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International
Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic
leukaemia after failure to hypomethylating agents.
Br J Haematol. 2024;204:898-909. PubMedAbstract available
CHEN N, Pan J, Zhou Y, Mao L, et al Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated
acute myeloid leukaemia.
Br J Haematol. 2024;204:861-870. PubMedAbstract available
February 2024
COSTA A, Breccia M How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
Br J Haematol. 2024;204:434-448. PubMedAbstract available
PARDANANI A, Reichard K, Tefferi A Advanced systemic mastocytosis-Revised classification, new drugs and how we
treat.
Br J Haematol. 2024;204:402-414. PubMedAbstract available
FUJI S, Yuda S, Tada Y, Kano M, et al A treatment strategy to mitigate the adverse effect of pretransplant
mogamulizumab on post-transplant clinical outcome in patients with aggressive
ATL.
Br J Haematol. 2024;204:e25-e27. PubMed
WANG Z, Fan Z, Wu Z, Xuan L, et al PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on
survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia
with allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:628-637. PubMedAbstract available
KUMAR J, Ewalt MD, Zhang Y, Yao J, et al Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic
leukaemia.
Br J Haematol. 2024;204:561-565. PubMedAbstract available
NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in
hypo- and normocellular MDS and AML.
Br J Haematol. 2024;204:724-729. PubMed
NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia:
Effects on cell metabolism and differentiation.
Br J Haematol. 2024;204:719-723. PubMed
RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al Biallelic inactivation of the NF1 tumour suppressor gene in juvenile
myelomonocytic leukaemia: Genetic evidence of driver function and implications
for diagnostic workup.
Br J Haematol. 2024;204:595-605. PubMedAbstract available
MARK C, Meshinchi S, Joyce B, Gibson B, et al Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
Br J Haematol. 2024;204:576-584. PubMedAbstract available
SHEN Y, Freeman JA, Kerridge I, Downe P, et al Repeated COVID-19 vaccination to maximum antibody response yields very low
mortality and hospitalisation rates in patients with CLL and MBL.
Br J Haematol. 2024;204:487-491. PubMedAbstract available
BAI L, Zhang ZX, Hu GH, Cheng YF, et al Long-term follow-up of haploidentical haematopoietic stem cell transplantation in
paediatric patients with high-risk acute myeloid leukaemia: Report from a single
centre.
Br J Haematol. 2024;204:585-594. PubMedAbstract available
January 2024
MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al Novel stratification for newly diagnosed acute myeloid leukaemia treated with
venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292. PubMed
NAVRKALOVA V, Plevova K, Radova L, Porc J, et al Integrative NGS testing reveals clonal dynamics of adverse genomic defects
contributing to a natural progression in treatment-naive CLL patients.
Br J Haematol. 2024;204:240-249. PubMedAbstract available
HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Br J Haematol. 2024;204:16-18. PubMedAbstract available
GJERTSEN BT How to discover the exceptional venetoclax responders in AML/MDS?
Br J Haematol. 2024;204:14-15. PubMed
GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al IGJ and SPATS2L immunohistochemistry sensitively and specifically identify
BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:229-239. PubMedAbstract available
BARON F, Nagler A, Galimard JE, Sanz J, et al Cord blood transplantation for AML: Comparable LFS in patients with de novo
versus secondary AML in CR1, an ALWP/EBMT study.
Br J Haematol. 2024;204:250-259. PubMedAbstract available
DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al Ratio of stemness to interferon signalling as a biomarker and therapeutic target
of myeloproliferative neoplasm progression to acute myeloid leukaemia.
Br J Haematol. 2024;204:206-220. PubMedAbstract available
NANAA A, He R, Foran JM, Badar T, et al Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia
and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Br J Haematol. 2024;204:171-176. PubMedAbstract available
MURPHY EL HTLV-1 and blood donation.
Br J Haematol. 2024;204:29-30. PubMedAbstract available
December 2023
HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al AML in the elderly-A global view.
Br J Haematol. 2023;203:760-773. PubMed
WU JF, Abid H, Szabo A, Abid MB, et al Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell
acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Br J Haematol. 2023;203:e117-e120. PubMed
HERRITY E, Pereira MP, Kim DDH Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell
transplantation: Mechanistic diversity and therapeutic directions.
Br J Haematol. 2023;203:722-735. PubMedAbstract available
MAHDI D, O'Nions J, Raj K, Baker R, et al Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a
watch and wait approach reasonable?
Br J Haematol. 2023;203:e114-e116. PubMed
QI P, Wang L, Li H, Wu Y, et al Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A
single-centre experience.
Br J Haematol. 2023;203:892-895. PubMed
PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al Final report of TKI discontinuation trial with dasatinib for the second attempt
of treatment-free remission after failing the first attempt with imatinib:
Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol. 2023;203:781-791. PubMedAbstract available
CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
Br J Haematol. 2023;203:699-700. PubMed
November 2023
NG JY, Joshi M, Choi P Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
Br J Haematol. 2023;203:668-672. PubMedAbstract available
BORLENGHI E, Roccaro AM, Cattaneo C Rethinking the definition of 'less intensive' for venetoclax-combining regimens
in acute myeloid leukaemia patients.
Br J Haematol. 2023;203:504-506. PubMedAbstract available
REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al Invasive fungal infection following venetoclax and posaconazole
co-administration.
Br J Haematol. 2023;203:593-598. PubMedAbstract available
OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al Blinatumomab differentially modulates peripheral blood and bone marrow immune
cell repertoire: A Campus ALL study.
Br J Haematol. 2023;203:637-650. PubMedAbstract available
BOOTH E, Backx M, Joshi A, Nizami H, et al Disseminated invasive aspergillosis in a patient treated with ibrutinib for
chronic lymphocytic leukaemia.
Br J Haematol. 2023;203:499-500. PubMed
DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al Cytidine deaminase status as a marker of response to azacytidine treatment in MDS
and AML patients.
Br J Haematol. 2023;203:625-636. PubMedAbstract available
MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic
leukaemia.
Br J Haematol. 2023;203:581-592. PubMedAbstract available
APOLITO V, Arrigo G, Vasseur L, Olivi M, et al Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early
mortality and survival in acute myeloid leukaemia patients treated with
hypomethylating agents and venetoclax.
Br J Haematol. 2023;203:e98-e101. PubMed
October 2023
MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product
varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the
treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170. PubMedAbstract available
PAN X, Chang Y, Ruan G, Wei F, et al Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia
patients and related molecular mechanisms.
Br J Haematol. 2023;203:212-223. PubMedAbstract available
MAHDI D, Spiers J, Rampotas A, Polverelli N, et al Updates on accelerated and blast phase myeloproliferative neoplasms: Are we
making progress?
Br J Haematol. 2023;203:169-181. PubMedAbstract available
SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al Focal adhesion kinase activation by calcium-dependent calpain is involved in
chronic lymphocytic leukaemia cell aggressiveness.
Br J Haematol. 2023;203:224-236. PubMedAbstract available
TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al Functional characterization and response to FLT3 inhibitors in acute myeloid
leukaemia with a non-canonical FLT3 mutation: A proof of concept.
Br J Haematol. 2023;203:327-330. PubMed
EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia
in a female patient after receiving an allo-transplant from her male sibling.
Br J Haematol. 2023;203:282-287. PubMedAbstract available
September 2023
BRECCIA M, Saglio G Interferon in chronic myeloid leukaemia: Is it useful for treatment-free
remission?
Br J Haematol. 2023;202:1087-1088. PubMedAbstract available
HADDAD FG, Kourie HR, Saleh K Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive
B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2023;202:1084-1086. PubMedAbstract available
IRANI YD, Hughes A, Kok CH, Clarson J, et al Immune modulation in chronic myeloid leukaemia patients treated with nilotinib
and interferon-alpha.
Br J Haematol. 2023;202:1127-1136. PubMedAbstract available
FENG H, Fu Y, Cui Z, Zhou M, et al Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia
by directly targeting BCR::ABL1.
Br J Haematol. 2023;202:1178-1191. PubMedAbstract available
PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Br J Haematol. 2023;202:1137-1150. PubMedAbstract available
PASTORE F, Gittinger H, Raab S, Tschuri S, et al Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q
aberrations and dismal outcome.
Br J Haematol. 2023;202:1165-1177. PubMedAbstract available
XIE M, Lu Y, Ouyang G, Li X, et al Dasatinib plus prednisone as induction and consolidation for adults with
Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2
trial.
Br J Haematol. 2023;202:1119-1126. PubMedAbstract available
MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al Hairy cell leukaemia with an IGH-BRAF fusion gene.
Br J Haematol. 2023;202:e67-e70. PubMed
BELHADJ M, Burroni B, Kosmider O, Willems L, et al Clinico-biological features, treatment and prognosis of primary myeloid sarcoma:
A French retrospective multi-centric observational study.
Br J Haematol. 2023;202:e50-e53. PubMed
August 2023
KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted
CTLs specific to HTLV-1 in ATL patients.
Br J Haematol. 2023;202:578-588. PubMedAbstract available
LOKE J, Upasani V, Gaskell C, Fox S, et al Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and
myelodysplastic syndromes.
Br J Haematol. 2023;202:498-503. PubMedAbstract available
SARTOR C, Brunetti L, Audisio E, Cignetti A, et al A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute
myeloid leukaemia in molecular failure.
Br J Haematol. 2023;202:599-607. PubMedAbstract available
BORRILL R, Poulton K, Kusyk L, Routledge A, et al Granulocyte transfusion during cord blood transplant for relapsed, refractory AML
is associated with massive CD8(+) T-cell expansion, significant cytokine release
syndrome and induction of disease remission.
Br J Haematol. 2023;202:589-598. PubMedAbstract available